Reuters logo
BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
November 15, 2017 / 9:48 PM / a month ago

BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc

* Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

* Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​

* Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​

* Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below